Abstract:
Combination of an open and a hidden excavation for constructing a vertical orthogonal top exhausting air duct structure of a deeply-buried subway station is provided. Four horizontal air ducts: left and right piston air ducts, an exhaust air duct, and a fresh air duct are thrown out of the underground, respectively, leading to left and right piston air shafts, an exhaust air shaft, a fresh air shaft, and an entrance/exit of fire-fighting. The fourth underground floor is communicated with the hall floor of the station main body, and the fifth underground floor is communicated with the running tunnel and the platform floor of the station main body. During operation, the train will enter and exit the station through the fifth underground floor of the air duct, and the piston air and heat will enter the four transverse air ducts through the air duct main body.
Abstract:
Combination of an open and a hidden excavation for constructing a vertical orthogonal top exhausting air duct structure of a deeply-buried subway station is provided. Four horizontal air ducts: left and right piston air ducts, an exhaust air duct, and a fresh air duct are thrown out of the underground, respectively, leading to left and right piston air shafts, an exhaust air shaft, a fresh air shaft, and an entrance/exit of fire-fighting. The fourth underground floor is communicated with the hall floor of the station main body, and the fifth underground floor is communicated with the running tunnel and the platform floor of the station main body. During operation, the train will enter and exit the station through the fifth underground floor of the air duct, and the piston air and heat will enter the four transverse air ducts through the air duct main body.
Abstract:
The present invention is directed to the development of novel exendin-4 derivatives exhibiting advantageous glucose-regulatory properties, and to methods of producing these derivatives, including recombinant methods in which these derivatives are produced by cleavage of a fusion protein containing multiple copies of the exendin-4 derivative peptide. The methods of the present invention can be used to simplify the process of producing the disclosed exendin-4 derivatives, thereby lowering the cost of their production.
Abstract:
The present invention provides a Magainin derivative peptide and method of production thereof. Also provided is a pharmaceutically composition comprising said Magainin derivative peptide and pharmaceutically acceptable carrier and/or pharmaceutically compatible binding agents. The Magainin derivative peptide of the present invention having amino acid sequence of the general formula shown as below: Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-Lys-Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-X-Asn-Y-Z-OH in which: X is an amino acid residue selected from the group consisting of Met, Ile and Leu; Y is an amino acid residue selected from the group consisting of Ser, Lys, Ile, Arg and Leu; and Z is Arg.
Abstract:
The present invention discloses a method of producing polypeptides, including insulinotropic GLP-1 (7-36) polypeptide and/or GLP-1 analogs, by ligating genes in a tandem way. Also disclosed are the recombinant polypeptides produced by such a method. Using the method of this invention, 1 to 32 copies of GLP-1 (7-36) and/or GLP-1 analog genes may be expressed in tandem and the desired polypeptide can be obtained after cleavage of a fusion protein and further processes of separation and purification thus making possible the production of recombinant polypeptides, including recombinant GLP-1 (7-36) and/or GLP-1 analogs on a large scale, at a significantly reduced production cost.
Abstract:
The present invention provides a Magainin derivative peptide and method of production thereof. Also provided is a pharmaceutically composition comprising said Magainin derivative peptide and pharmaceutically acceptable carrier and/or pharmaceutically compatible binding agents. The Magainin derivative peptide of the present invention having amino acid sequence of the general formula shown as below: Gly-Ile-Gly-Lys-Phe-Leu-His-Ser-Ala-Lys-Lys- Phe-Gly-Lys-Ala-Phe-Val-Gly-Glu-Ile-X-Asn-Y-Z-OH in which: X is an amino acid residue selected from the group consisting of Met, Ile and Leu; Y is an amino acid residue selected from the group consisting of Ser, Lys, Ile, Arg and Leu; and Z is Arg.